Who are Endogenex's investors?

Endogenex's investors include Arboretum Ventures, Hatteras Venture Partners, Intuitive Ventures, Longitude Capital, Lumira Ventures, Southeast Minnesota Capital Fund.

How much funding has Endogenex raised?

Endogenex has disclosed $50M raised across 1 of its 3 known rounds.

Where is Endogenex headquartered?

Endogenex is headquartered in Minneapolis, US.

Endogenex

Minneapolis, US · Founded 2017 · 28 employees on LinkedIn · 6 known investors

Find your way into Endogenex

Each arrow is one introduction. Sign up to fill in the first one.

240 people can intro you to Melanie

Ask Jim Surek to introduce you to Melanie Hess

You →Jim · together at Osprey Medical →Melanie

107 people can intro you to Krissy

Ask Jamie Chen to introduce you to Krissy Wright

You →Jamie · together at Paragon28 →Krissy

Your email: who you already know at Endogenex, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Endogenex team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.

Digital Health Healthtech Medical Devices

Founders & leadership

Stacey PughLeadership (CEO)

Chris Sorli, MD, PhDChief Medical Officer

Krissy Wright Chief Financial OfficerKrissy Wright is Chief Financial Officer at Endogenex, a clinical-stage medical device company developing a non-thermal pulsed electric field therapy for type 2 diabetes. She has spent the past two years at Endogenex and brings experience in capital strategy, multi-functional operations leadership, and scaling companies toward commercial readiness.

Lian Cunningham, MD, PhDVP Clinical Affairs

Melanie Hess Regulatory Affairs LeadershipVice President at Endogenex focused on regulatory affairs and compliance strategy. Hess brings experience in regulatory submission strategy, quality systems, and healthcare operations across multiple device classifications.

Matt CambronneTechnical/Engineering Leadership

Barham K. Abu DayyehCo-inventor, pulsENDO system

Investors · 6

Arboretum Ventureslisted by Arboretum VenturesAnn Arbor · $5M – $15M

How we know: Arboretum Ventures's portfolio page · funding news · Not right? Tell us

Hatteras Venture Partnerslisted by Hatteras Venture PartnersResearch Triangle · $500K – $4M

How we know: Hatteras Venture Partners's portfolio page · Not right? Tell us

Intuitive Ventureslisted by Intuitive VenturesSunnyvale

How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Lumira Ventureslisted by Lumira VenturesToronto · $1M – $10M

How we know: Lumira Ventures's portfolio page · Not right? Tell us

Southeast Minnesota Capital Fundlisted by Southeast Minnesota Capital FundRochester

How we know: Southeast Minnesota Capital Fund's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 3 rounds · 2024–2026

$50MSeries C ExtensionMar 2026 · 2 sources
Source ↗
Undisclosed amountSeries CJun 2024
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

OrogentxOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

PhigenixPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.

arGEN-XThe company develops therapies for people with severe autoimmune diseases.

Companies working in the same space as Endogenex.

In the news

Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approvalendogenex.com · Mar 2026

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetesprnewswire.com · Jun 2024

Frequently asked questions

What does Endogenex do?: Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
Who are Endogenex's investors?: Endogenex's investors include Arboretum Ventures, Hatteras Venture Partners, Intuitive Ventures, Longitude Capital, Lumira Ventures, Southeast Minnesota Capital Fund.
How much funding has Endogenex raised?: Endogenex has disclosed $50M raised across 1 of its 3 known rounds.
Where is Endogenex headquartered?: Endogenex is headquartered in Minneapolis, US.